Fredericamycin (FDM) A, a pentadecaketide featuring two sets of
peri-hydroxy tricyc
lic aromaticmoieties connected through a unique chiral spiro carbon center, exhibits potent cytotoxicity and has beenstudied as a new type of anticancer drug lead because of its novel molecular architecture. The
fdm genecluster was loca
lized to 33-kb DNA segment of
Streptomyces griseus ATCC 49344, and its involvement inFDM A biosynthesis was proven by gene inactivation, complementation, and heterologous expressionexperiments. The
fdm cluster consists of 28 open reading frames (ORFs), encoding a type II polyketidesynthase (PKS) and tailoring enzymes as well as several regulatory and resistance proteins. The FDMPKS features a KS
subunit with heretofore unseen tandem cysteines at its active site, a KS
subunit thatis distinct phylogenetically from KS
of hexa-, octa-, or decaketide PKSs, and a dedicated phosphopantetheinyl transferase. Further study of the FDM PKS could provide new insight into how a type II PKScontrols chain length in aromatic polyketide biosynthesis. The availabi
lity of the
fdm genes, in vivocharacterization of the
fdm cluster in
S. griseus, and heterologous expression of the
fdm cluster in
Streptomyces albus set the stage to investigate FDM A biosynthesis and engineer the FDM biosyntheticmachinery for the production of novel FDM A analogues.